[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurological-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurological-disorders":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,73,111,143,174,195,223,247,281,311,338,375,408],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":53,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100270060","neurologic-stem-cell-treatment-study-100270060",false,"NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[54,55,31,32,56,57,45,58,36,51,48,59],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","RECRUITING","2026-06-24",{"date":63,"type":64},"2026-06-26","ACTUAL",{"date":66,"type":64},"2016-06",{"date":68,"type":21},"2028-07-31",{"name":70,"class":71},"MD Stem Cells","INDUSTRY",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100172884","product-surveillance-registry-100172884","NCT01524276","Product Surveillance Registry","Medtronic Product Surveillance Registry","PSR","Inclusion Criteria:\n\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n* Patient has or is intended to receive or be treated with an eligible Medtronic product\n* Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n* Patient who is, or will be, inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results",{"count":82,"type":21},100000,"OBSERVATIONAL","The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.",[86,87,30,88,89,90,91,92,93,94,95,96,97,98,99,100],"Cardiac Rhythm Disorders","Urological Disorders","Cardiovascular Disorders","Digestive Disorders","Intracranial Aneurysm","Mechanical Circulatory Support","Respiratory Therapy","Aortic, Peripheral Vascular and Venous Disorders","Minimally Invasive Surgical Procedures","Diagnostic Techniques and Procedures","Surgical Procedures, Operative","Renal Insufficiency","Neurovascular","Coronary Artery Disease","Ear, Nose and Throat Disorder","2026-06-15",{"date":103,"type":64},"2026-06-17",{"date":105,"type":4},"2012-01",{"date":107,"type":21},"2040-01",{"name":109,"class":71},"Medtronic",395,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":142},"100397953","exhaled-breath-analysis-by-secondary-electrospray-ionization---mass-spectrometry-in-children-and-adolescents-100397953","NCT04461821","Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents","Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents (EBECA)","EBECA","Inclusion Criteria:\n\n* Age 0 ≤ 22 years at study entry and signed informed consent\n\nAdditional inclusion criteria for respiratory disease population:\n\n* Acute disease: - Acute signs for a respiratory disease, indicated by e.g. increased work of breathing (e.g. dyspnea, increased respiratory rate), cough or wheezing.\n* Chronic disease: - Suspected or confirmed chronic airway disease (e.g. asthma).\n\nAdditional inclusion criteria for neurological disease population:\n\n* Acute disease: - Acute presentation or report within 24 hours of any signs of neurological deficit (motor function, sensoneural, or verbal).\n* Chronic disease: - Confirmed chronic neurologic disease (e.g. childhood epilepsy).\n\nAdditional inclusion criteria for T1D disease population:\n\n* Acute disease: - Hyperglycemia and\u002For pH (venous) \\\u003C7.3, bicarbonate \\>10 mmol\u002FL, increased levels of acetone in blood or urine in the context of newly diagnosed or known T1D.\n* Chronic disease: - Confirmed diagnosis of T1D\n\nExclusion Criteria:\n\n* Physical or intellectual impairment precluding protocol adherence.\n\nAdditional exclusion criteria for respiratory disease population:\n\n* Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and\u002For pharmacological treatment and is associated with an inflammatory response, relevant congenital defects\n\nAdditional exclusion criteria for neurological disease population:\n\n* Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and\u002For pharmacological treatment and is associated with an inflammatory response, relevant congenital defects.\n\nAdditional exclusion criteria for T1D population:\n\n* Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), relevant congenital defects.","22 Years",{"count":121,"type":21},3600,"This study is to investigate breath analysis (breath metabolomics) combined with established bioinformatic tools as a platform for companion diagnostics.",[124,30,125],"Respiratory Diseases","Type 1 Diabetes",[127,128,129,130,131],"Exhaled breath analysis","Therapeutic drug monitoring (TDM)","Secondary Electrospray ionization - mass spectrometry (SESI-MS)","breath analysis platform","breath metabolomics","2026-05-04",{"date":134,"type":64},"2026-05-08",{"date":136,"type":64},"2020-09-11",{"date":138,"type":21},"2030-07",{"name":140,"class":141},"University Children's Hospital Basel","OTHER",1,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":151,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100634406","device-for-driving-simulation-for-the-rehabilitation-of-balance-and-proprioception-100634406","NCT07539272","Device for Driving Simulation for the Rehabilitation of Balance and Proprioception","A Multicenter Interventional Study on the Use of a Driving Simulator to Assess the Safety and Usability of the System and Its Impact on Motor and Cognitive Performance in the Rehabilitation of Patients With Neurological Disorders","DRIVESIM","Inclusion Criteria:\n\n* Patients: adults aged 18 to 80 years.\n* Patients: confirmed diagnosis of one of the following chronic neurological conditions: stroke, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or mild cognitive impairment (MCI).\n* Patients: able to understand and follow study procedures and provide informed consent.\n* Healthy volunteers: adults aged 18 to 65 years.\n* Healthy volunteers: able to understand and follow study procedures and provide informed consent.\n* Healthy volunteers: rehabilitation staff members from the participating centers.\n\nExclusion Criteria:\n\n* Patients: severe psychiatric disorders or cognitive disorders that impair the ability to complete cognitive tests and self-report questionnaires.\n* Patients: unable to provide informed consent.\n* Patients: moderate to severe cognitive impairment, defined as an ECAS score below 81.92 in participants with ALS or a Raven's Matrices score below 18.36 in participants with mild cognitive impairment.\n* Patients: neurological or physical conditions that significantly limit lower-limb use and prevent standing on the platform, including lower-limb muscle strength of 3 or less on the Medical Research Council (MRC) scale.\n* Patients: body weight greater than 100 kg.\n* Patients: current or recent participation, within the last 3 months, in other rehabilitation programs or interventions that could affect study results.\n* Patients: alcohol or substance dependence that could compromise safety during training sessions.\n* Patients: unstable health conditions that could make use of the DRIVESIM and\u002For head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions.\n* Healthy volunteers: health conditions that could make use of the DRIVESIM and\u002For head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions.\n* Healthy volunteers: any motor disability.",true,"80 Years",{"count":154,"type":21},60,[24],"The DriveSim clinical trial investigates a dynamic driving simulator designed to train and assess functional motor and cognitive skills in individuals with neurological disorders. The study addresses a critical need in current rehabilitation practice, where maintaining patient engagement and providing ecologically valid training environments are essential yet challenging. Neurological conditions such as stroke, Parkinson's disease, amyotrophic lateral sclerosis and mild cognitive impairment often result in deficits in balance, proprioception, coordination, attention and motor planning, all of which critically affect daily functioning and driving ability. The novelty of this study lies in the integration of a three-degree-of-freedom motion platform with active steering, customizable haptic and inertial feedback, and adaptive task modules in a virtual urban scenario. This enables controlled, multisensory rehabilitation sessions that combine motor, vestibular and cognitive stimuli in a single system. The primary objective of the trial is to evaluate the safety, usability and feasibility of the DriveSim platform in both healthy individuals and patients with neurological impairment. Secondary objectives include assessing its impact on postural control, trunk and head stability, upper and lower limb motor performance, cognitive functions, perceived stress and fatigue, and quality of life. The study also aims to support the development of adaptive software capable of automatically adjusting task difficulty based on patient performance. By integrating functional tasks such as slalom, speed control, line keeping and reaction tests with customizable sensory feedback, this research has the potential to enhance the ecological validity of rehabilitation and to provide individualized motor-cognitive training. The expected outcome is a more engaging, adaptable and measurable rehabilitation pathway that may improve functional independence and support safer driving-related abilities in neurological populations.",[30,158],"Health Adult Subjects",[160,161,162,163],"neurological rehabilitation","driving simulator","dynamic platform","motor-cognitive training","NOT_YET_RECRUITING","2026-04-13",{"date":167,"type":64},"2026-04-20",{"date":169,"type":21},"2026-04",{"date":171,"type":21},"2026-11",{"name":173,"class":141},"University of Pavia",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":151,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":193,"leadSponsor":194,"locationsCount":4},"100631611","a-multicenter-interventional-study-on-the-use-of-a-3-degree-of-freedom-3dof-platform-to-evaluate-the-safety-and-usability-of-the-system-and-its-impact-on-balance-proprioception-and-neurological-deficits-in-the-rehabilitation-of-patients-with-neurological-disorders-100631611","NCT07502937","A Multicenter Interventional Study on the Use of a 3-Degree-of-Freedom (3DOF) Platform to Evaluate the Safety and Usability of the System and Its Impact on Balance, Proprioception, and Neurological Deficits in the Rehabilitation of Patients With Neurological Disorders.","3DOF","Inclusion Criteria:\n\n* Patients: adults aged 18 to 80 years.\n* Patients: confirmed diagnosis of one of the following chronic neurological conditions: stroke, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or mild cognitive impairment (MCI).\n* Patients: able to understand and follow study procedures and provide informed consent.\n* Healthy volunteers: adults aged 18 to 65 years.\n* Healthy volunteers: able to understand and follow study procedures and provide informed consent.\n* Healthy volunteers: rehabilitation staff members from the participating centers.\n\nExclusion Criteria:\n\n* Patients: severe psychiatric disorders or cognitive disorders that impair the ability to complete cognitive tests and self-report questionnaires.\n* Patients: unable to provide informed consent.\n* Patients: moderate to severe cognitive impairment, defined as an ECAS score below 81.92 in participants with ALS or a Raven's Matrices score below 18.36 in participants with mild cognitive impairment.\n* Patients: neurological or physical conditions that significantly limit lower-limb use and prevent standing on the platform, including lower-limb muscle strength of 3 or less on the Medical Research Council (MRC) scale.\n* Patients: body weight greater than 100 kg.\n* Patients: current or recent participation, within the last 3 months, in other rehabilitation programs or interventions that could affect study results.\n* Patients: alcohol or substance dependence that could compromise safety during training sessions.\n* Patients: unstable health conditions that could make use of the 3DoF Platform and\u002For head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions.\n* Healthy volunteers: health conditions that could make use of the 3DoF Platform and\u002For head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions.\n* Healthy volunteers: any motor disability.",{"count":154,"type":21},[24],"This multicenter interventional study aims to evaluate a three-degrees-of-freedom dynamic platform (3DoF Platform) designed to support rehabilitation of balance, proprioception, and motor and cognitive functions in patients with neurological disorders. The device integrates a mobile platform capable of roll, pitch, and vertical translation movements, a markerless motion-capture system, and an interactive environment delivered through a monitor or virtual reality headset. Compared with conventional rehabilitation systems, it offers an additional vertical degree of freedom and increased proprioceptive stimulation, with the ability to customize exercises according to individual patient capabilities. The clinical conditions under investigation include Parkinson's disease, post-stroke motor impairment, amyotrophic lateral sclerosis, and mild cognitive impairment, all of which are associated with deficits in balance and proprioception. The novelty of this study lies in the combined use of the 3DoF platform, the markerless acquisition system, and exergames integrated with a mathematical model that adapts the platform's dynamic response in real time. The primary objective is to assess the usability, feasibility, and safety of the device. Secondary objectives include evaluating the impact of the intervention on balance, motor performance, cognitive functions, stress, fatigue, and quality of life, as well as comparing conventional rehabilitation with and without the addition of the device. The study involves 45 patients and 15 healthy volunteers and is structured into an initial phase of testing on healthy subjects and a subsequent randomized two-arm treatment phase for patients.",[30,158],[186,187,188,160],"3DoF Platform","proprioception","exergame","2026-03-31",{"date":191,"type":64},"2026-04-06",{"date":169,"type":21},{"date":171,"type":21},{"name":173,"class":141},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":151,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100629680","a-muscle-brain-interplay-study-in-neurological-disorders-100629680","NCT07477821","A Muscle-brain Interplay Study in Neurological Disorders","A Translational Approach to Characterize the Muscle-brain Interplay in Neurological Non-communicable Diseases. The M-Brain Project","M-Brain","Inclusion Criteria:\n\nfor Good aging group:\n\n* Subjects aged 60 years or older\n* Frailty Index below the pathological cut-off (\\>0.25)\n* Absence of general cognitive impairment (MMSE \\> 24 points)\n* Absence of a diagnosis of sarcopenia\n\nfor Bad aging group:\n\n* Patients aged over 60 years\n* Exclusive presence of one of the following diagnoses:\n\n  1. Definite, probable, or probable laboratory-supported Amyotrophic Lateral Sclerosis (ALS), either sporadic or familial, according to the revised El Escorial Criteria for ALS diagnosis.\n  2. Parkinson's disease (PD) according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., Mov Disord., 2015 Oct; 30(12): 1591-1601).\n  3. Alzheimer's disease (AD), possible or probable, according to international diagnostic guidelines.\n  4. Diagnosis of severe acquired brain injury according to the Italian Guidelines for the Care of Patients in Vegetative State and Minimally Conscious State 2011 (approved by the Unified Conference on May 5, 2011 - Ministry of Health, Italy), with the presence of Sarcopenia.\n  5. Presence of Mild Cognitive Impairment (MCI), subjective memory complaint, or deficit in a single cognitive domain, according to international criteria and in absence of established neurological diseases and sarcopenia.\n  6. Presence of Sarcopenia as defined by the EWGSOP2 Sarcopenia Consensus, in the absence of cognitive deficits and established neurological diseases.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Presence of severe and\u002For acute comorbidities (e.g., uncontrolled diabetes, heart failure, or a diagnosis of oncological disease), as determined by the research team.\n* Evidence of other previous neurological or psychiatric disorders involving the cognitive domain.\n* Uncontrolled or complicated systemic diseases or history of traumatic brain injury.\n* For subjects with Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS), individuals with a history of epilepsy will also be excluded.","60 Years",{"count":205,"type":21},150,"Despite the improvements in life expectancy, neurodegenerative diseases (NDGs) have become the most dreaded disorders of older people. Aged brains show characteristic changes that are linked to neurodegeneration raising the question of whether these hallmarks represent the harbingers of NDGs. Lifestyle factors including, in particular physical exercise, have given particular attention to factors associated to movement issue as ones of the major factors in modulating the risk of developing NDGs, emphasizing the interest in the muscle-brain axis. Indeed, one of the crucial systems severely affected in several neuromuscular diseases is the loss of effective connection between muscle and nerve, and the neuromuscular junction (NMJ) represents the critical region at the level of which the two entities communicate.\n\nEven if controversy exists on whether pathological events beginning at the NMJ precede or follow loss of motor units, some recent data highlight as NGDs (e.g. Amyotrophic Lateral Sclerosis, Alzheimer's Disease, and Parkinson's Disease) and Aging share some common pathologic features such as the loss of fast-twich fiber, a decreased number of synaptic vesicles and sarcopenia giving evidence supports the notion that NMJ dismantlement can occur independently from motor neuron degeneration and may represent an early pathogenic signature of muscle-nerve communication defects.\n\nThe M-Brain project is an observational, analytical case-control study that will apply a new approach to interpret data underling the NMJ dismantlement in NDGs patients by comparing their clinical and biological information with data obtained from people who have had a so called \"good aging\" and those who have had a \"bad aging\".\n\nThe study will collect data useful to identify potential predisposing or risk factors for the subsequent development of a NDGs or able to predict the phenotype traiectories of selected pathologies with differerent movement levels. The combination of a muscular and neurological phenotyping and a biological characterization combining biomarkers, miRNA and extracellular vesicle (EV) assessments will allow to better identify the determinants of muscle-brain cross-talk that can then be used as potential indicators for the definition of critical morphological and functional components involved in aging and some NGDs. The project then will aim to identify phenotyope trajectories of patients giving particular attention to the brain-muscle axis and movement issues in order to provide information useful for future clinical strategies able to minimaze risk\u002Fpredisponent Factors.",[30,158],[209,210,211,212],"muscle","brain","aging","Neuromuscolar","2026-03-12",{"date":215,"type":64},"2026-03-17",{"date":217,"type":64},"2025-07-24",{"date":219,"type":21},"2027-02-28",{"name":221,"class":141},"Istituti Clinici Scientifici Maugeri SpA",4,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":142},"100622478","cognitive-recovery-via-sensor-based-robotic-upper-limb-rehabilitation-in-neurological-disorders-100622478","NCT07384143","Cognitive Recovery Via Sensor-based Robotic Upper Limb Rehabilitation in Neurological Disorders","Exploring Cognitive Recovery: the Impact of Sensor-based Robotic Rehabilitation in Neurological and Neurodegenerative Disorders","CROSS-ND","Inclusion Criteria:\n\n* Age 18-75 years;\n* FMA-UL 0-31: eligible for exoskeletons and robotic devices with high support. (Armeo Power, Amadeo, Motore)\n* FMA-UL 32-47: eligible for end-effectors with medium support. (Armeo Spring, Hand Tutor, Diego)\n* FMA-UL 48-52: eligible for sensor-based with low support. (Pablo, Diego, Armeo Senso)\n* MoCA: ≤ 20\n\nExclusion Criteria:\n\n* Severe cognitive disorders\n* Behavioral disorders\n* Sensory disorders","75 Years",{"count":233,"type":21},189,[24],"The goal of this clinical trial is to learn if sensor-based robotic upper limb rehabilitation can improve cognitive and motor functions in adults with neurological and neurodegenerative disorders, including Parkinson's disease, multiple sclerosis, and stroke. The main questions it aims to answer are:\n\nDoes sensor-based robotic rehabilitation improve cognitive functions such as attention, memory, and executive functions? Does this rehabilitation lead to better motor recovery and daily functioning compared to conventional therapy? Researchers will compare the experimental group receiving robotic rehabilitation with cognitive tasks to the control group receiving conventional therapy to see if the robotic approach leads to greater improvements in both cognitive and motor outcomes.\n\nParticipants will:\n\nReceive upper limb rehabilitation using robotic devices and virtual reality-based exercises or conventional therapy Complete a series of neuropsychological assessments before and after the intervention to measure cognitive changes Complete motor function tests before and after the intervention to evaluate physical improvements Participate in 25 training sessions, 2-3 times per week, each lasting 60 minutes",[237,56,31,30],"PARKINSON DISEASE (Disorder)","2026-01-26",{"date":240,"type":64},"2026-02-03",{"date":242,"type":64},"2025-02-11",{"date":244,"type":21},"2030-02-11",{"name":246,"class":141},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":257,"conditions":258,"keywords":262,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":142},"100615956","a-model-for-continuous-care-of-fragile-patients-100615956","NCT07299344","A Model for Continuous Care of Fragile Patients","Un Modello di Presa in Carico Continua Del Paziente Fragile","AFTER","Inclusion criteria:\n\n* Adult medically fragile patients with one of the following neurological conditions: mild-to-moderate stroke (Rankin ≤ 3), Multiple Sclerosis (EDSS ≤ 6.5), Parkinson's disease or parkinsonisms, neuromuscular diseases; or orthopedic conditions: femur, pelvis, or humerus fracture.\n* Able to walk independently, with or without assistive devices.\n* Adequate cognitive function (MMSE ≥ 24).\n* Patient or caregiver owns and can use a mobile device with internet\u002Fdata connection.\n* Presence of a cognitively capable, cooperative caregiver willing to participate in the study.\n\nExclusion criteria:\n\n* Patients with severe neurological or orthopedic conditions who cannot walk independently, even with assistive devices.\n* Patients with moderate or severe cognitive impairment (MMSE \\\u003C 24).\n* Patients with Barthel Index \\> 60.\n* Patients or caregivers unable to use a mobile device or without internet\u002Fdata connection.\n* Patients without a cooperative, cognitively capable caregiver.",{"count":256,"type":21},100,"This observational study aims to monitor functional status and identify potential declines in the functioning of medically fragile patients with neurological and\u002For orthopedic conditions, representing an added value for ensuring appropriate patient management. This approach improves system efficiency and supports a proactive strategy that promotes the appropriate use of resources.",[30,259,260,261],"Orthopedic Disorders","Functional Decline","Fragile and More Vulnerable",[263,260,264,30,265,266,267,268,269,270,271],"Functional Monitoring","Medically Fragile Patients","Orthopedic Conditions","Rehabilitation","Proactive Care Model","Continuous Patient Management","Rehabilitation Setting","Early Detection of Functional Changes","telemedicine","2025-12-09",{"date":274,"type":64},"2025-12-23",{"date":276,"type":21},"2025-12",{"date":278,"type":21},"2028-06",{"name":280,"class":141},"Azienda Sanitaria Locale CN2 Alba-Bra",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":151,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":289,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":142},"100613552","validation-of-the-viradia-app-for-neurological-and-cognitive-diagnostics-in-virtual-reality-100613552","NCT07268079","Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality","Validation Study of VIRADIA: A Virtual Reality Diagnostic Platform for the Assessment of Neurological and Cognitive Functions","VIRADIA","Inclusion Criteria:\n\n* Age 18-80 years.\n* Ability to provide informed consent.\n* Adequate vision and hearing to complete testing.\n* For the neurological group: confirmed diagnosis of a neurological disorder (e.g., Parkinson's disease, multiple sclerosis, or similar).\n* For the control group: no history of neurological or psychiatric disease.\n\nExclusion Criteria:\n\n* Severe cognitive impairment (MMSE \\\u003C 24 or equivalent clinical judgment).\n* Acute neurological or psychiatric condition interfering with testing.\n* Severe motor disability preventing task performance (e.g., inability to use VR controller).\n* Current substance abuse.\n* Uncorrected visual impairment or vestibular disorder leading to intolerance of VR.",{"count":290,"type":21},200,"The VIRADIA study aims to validate and assess the reliability of a newly developed Virtual Reality (VR) diagnostic platform designed for neurological and cognitive testing. The goal is to determine whether the VR versions of nine commonly used clinical tests measure the same constructs and provide comparable results to their traditional face-to-face or paper-based forms.\n\nThe study includes two groups of participants: (1) healthy volunteers and (2) patients with neurological diagnoses. Each participant will complete both the standard and the VR versions of the tests, with the order of administration randomly assigned. The tested functions cover fine motor skills, gait and balance, attention, executive function, processing speed, and visuospatial abilities.\n\nThe following tests are included in the VR platform: 9-Hole Peg Test (9HPT), 6 Meter Walk Test, Timed Up and Go - Manual (TUG-M), Functional Reach Test (FRT), Symbol Digit Modalities Test (SDMT), Clock Drawing Test (CDT), Trail Making Test (TMT A\u002FB), Stroop Test, and SATURN Test.\n\nParticipants will first provide informed consent and basic demographic information. They will then complete all tests in both modalities (standard and VR), with appropriate breaks between tasks.\n\nThe study is observational, within-subjects, and paired in design. Primary outcomes include correlation and agreement between VR and standard test scores (validity). Data will be analyzed using paired statistical methods, including Pearson\u002FSpearman correlations, Bland-Altman analysis, and Intraclass Correlation Coefficients (ICC).\n\nNo medication or invasive intervention is used in this study. The VR testing is non-invasive and carries minimal risk. The study has been approved by the Ethics Committee of the Nitra Self-Governing Region (Approval No. 09I05-03-804).\n\nThe results will provide evidence for the validity and reliability of VR-based diagnostics and support the use of the VIRADIA platform as a safe, standardized tool for neurological and cognitive assessment.",[30,51,293,29],"Motor Impairment",[295,296,297,298,299,300,301],"Virtual Reality","Neurological Diagnostics","Cognitive Assessment","Motor Function","Neuropsychology","Validity","Digital Health","2025-12-03",{"date":304,"type":64},"2025-12-05",{"date":306,"type":21},"2025-12-01",{"date":308,"type":21},"2026-05-01",{"name":310,"class":141},"Gametherapy",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":142},"100603056","evaluation-of-the-wheelchair-school-drivkraft-a-clinical-study-100603056","NCT07131553","Evaluation of the Wheelchair School (Drivkraft) a Clinical Study","Utvärdering av Rullstolsskolan Drivkraft en Klinisk Studie av Ett beprövat Koncept","Inclusion Criteria:\n\n* Participant in the Drivkraft Wheelchair school at Aleris Rehab Station\n* Adult with neurological diagnosis using manual wheelchair\n\nExclusion Criteria:\n\n* Persons with Parkinsons Disease\n* Persons with too limited Swedish language skills to fill in study forms or make a signed consent\n* Persons with cognitive impairments affecting their ability to fill in study forms or make a signed consent",{"count":319,"type":21},80,[24],"This project will evaluate the Wheelchair School with the Drivkraft Methodology in a clinical setting. Participants are adults with chronic neurological diagnoses. For a person requiring a wheelchair, a well-functioning, individually adapted wheelchair and good maneuvering skills are essential for an independent daily life. These factors are also crucial in reducing the risk of secondary complications and pain. The Wheelchair School was founded in the 1990s, is provided by referral and both peer mentors and physiotherapists collaborate. It includes wheelchair prescription and adjustments, individually adapted wheelchair skills training, and theoretical lessons in group during 16 half-day sessions.\n\nThe overarching aim is to evaluate the intervention Wheelchair school with the Drivkraft method, for wheelchair skills and patient safety for persons with chronic neurological diagnoses in a Swedish context. Also to evaluate the psychometric properties of the Drivkraft Manouevering Test (DWMT) for wheelchair skills.",[30,323,266],"Wheelchair Mobility",[325,326,327,328],"wheelchair skills","spinal cord injury","multiple sclerosis","wheelchair user","2025-08-12",{"date":331,"type":64},"2025-08-20",{"date":333,"type":21},"2025-10-01",{"date":335,"type":21},"2027-12",{"name":337,"class":141},"Karolinska Institutet",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":356,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":142},"100585068","act-for-mental-health-in-neurological-disorders-100585068","NCT06897553","ACT for Mental Health in Neurological Disorders","Acceptance and Commitment Therapy- Based Group Therapy for Mental Health in Neurological Disorders","Inclusion Criteria:\n\n* Value above a cut-off of the DASS-21 subscales (depression \\> 10, anxiety \\> 6, and stress \\> 10)\n* Sufficient cognition and language ability (clinical rating)\n* Sufficient therapy motivation (clinical rating)\n\nExclusion Criteria:\n\n* Behavioral disorders (e.g., high irritability or apathy in clinical rating)\n* Other severe mental disorder (dementia, psychosis, personality disorders, intellectual disability)\n* Simultaneous psychotherapy or neuropsychological therapy",{"count":346,"type":21},44,[24],"The goal of this clinical trial is to examine the efficacy of this manual for mental health in people with mixed neurological disorders, including post-COVID. These conditions are often associated with cognitive impairment, which may hamper the effects of psychoterapy. Executive functioning and especially the ability to abstract thinking may be useful for individuals using Acceptance and Commitment Therapy. Therefore, the main questions research questions are:\n\n* Is this intervention effective in improving mental health?\n* Do executive functions predict the extent of social participation and mental health at the end of therapy? Participants will take part in 8 weekly group therapy sessions of 100 minutes each.",[30,350,351,352,353,354,355],"Mental Health","Executive Function (Cognition)","Depression\u002FAnxiety","Stress","Brain Injury","Post-COVID",[357,358,359,360,361,362,363,364,365,355],"Acceptance and Commitment Therapy (ACT)","group therapy","neurological disorders","brain injury","anxiety","stress","depression","executive functioning","abstraction ability","2025-03-25",{"date":368,"type":64},"2025-03-27",{"date":370,"type":64},"2024-12-01",{"date":372,"type":21},"2026-12-31",{"name":374,"class":141},"Bielefeld University",{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":151,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":385,"briefSummary":386,"conditions":387,"keywords":392,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":142},"100578748","efficacy-of-shock-wave-therapy-in-post-stroke-muscle-spasticity-management-100578748","NCT06815328","Efficacy of Shock Wave Therapy in Post-Stroke Muscle Spasticity Management","Efficacy of Shock Wave Therapy in Patients with Muscle Spasticity After a Stroke","SWT-PI","\"Inclusion Criteria\":\n\n* Adults aged 18 years or older.\n* Confirmed diagnosis of stroke (ischemic or hemorrhagic) at least 6 months prior to enrollment.\n* Clinically diagnosed muscle spasticity, measured by the Modified Ashworth Scale (MAS), with a score of 0 to 3.\n* Stable medical condition that permits participation in the intervention.\n* No significant changes in spasticity-related treatment for at least 3 months prior to the study.\n* Ability to provide written informed consent to participate in the study.\n* Ability to attend weekly sessions and follow-up visits as required.\n\n\"Exclusion Criteria\":\n\n* Severe spasticity or contractures unresponsive to prior treatments.\n* Contraindications to Shock Wave Therapy, including:\n* Local infections in the treatment area.\n* Known or suspected malignancy near the treatment site.\n* Severe bleeding disorders or anticoagulation therapy.\n* Pregnancy.\n* Neurological conditions other than stroke that could interfere with study outcomes (e.g., Parkinson's disease, multiple sclerosis).\n* Recent treatments that might interfere with spasticity assessment, including:\n* Injections of botulinum toxin within the past 6 months.\n* Recent surgery or other interventions targeting spasticity.\n* Cognitive impairment or other conditions preventing the participant from following instructions or completing study tasks.\n* Severe cardiovascular, renal, or hepatic disease that might complicate therapy or participation.\n* Inability to commit to follow-up visits or complete the intervention protocol due to logistical, mobility, or health-related issues.",{"count":384,"type":21},50,[24],"The goal of this clinical trial is to evaluate the efficacy and safety of shock wave therapy (SWT) in reducing muscle spasticity in patients who have suffered a stroke. The main questions it aims to answer are:\n\nDoes SWT reduce muscle tone and improve joint range of motion in post-stroke patients with spasticity? Does SWT improve the quality of life for these patients? What side effects, if any, occur during or after SWT? Researchers will compare SWT to conventional spasticity treatments to determine its effectiveness and potential advantages.\n\nParticipants will:\n\nUndergo SWT sessions as part of their rehabilitation protocol over a period of 8 weeks.\n\nAttend follow-up visits to assess muscle tone, joint mobility, and overall functional improvement.\n\nComplete quality-of-life questionnaires to measure the therapy's impact on daily living.",[31,388,389,390,30,391],"Spasticity","Post-stroke","Muscle Hypertonia","Physiotherapy",[393,394,395,396,397,398],"Shock Wave Therapy","Post-Stroke Spasticity","Non-Invasive Therapy","Quality of Life","Neurological physical therapy","Muscle Hypertonia Treatment","2025-03-09",{"date":401,"type":64},"2025-03-12",{"date":403,"type":21},"2025-03-15",{"date":405,"type":21},"2025-04-30",{"name":407,"class":141},"University of Oviedo",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":17,"minAge":415,"maxAge":18,"enrollmentInfo":416,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":4},"100567441","neurologocal-symptoms-in-chd-100567441","NCT06668233","Neurologocal Symptoms in CHD","Neurocognitive Disorders in Children With Congenital Heart Disease","Inclusion Criteria:\n\n\\- Children from 3 years to 18 years with congenital heart disease\n\nExclusion Criteria:\n\n* New born infants. Children with normal heart. Children with chromosomal or metabolic disease.","3 Years",{"count":256,"type":21},"The aim of the study is to determine neurological and cognitive disorders in children with congenital heart disease for early diagnosis and treatment",[30],"2024-10-30",{"date":421,"type":64},"2024-10-31",{"date":423,"type":21},"2024-10",{"date":425,"type":21},"2025-11",{"name":427,"class":141},"Assiut University"]